Patient-first cell therapy
TCRCure Biopharma Ltd. aims to develop next generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead to a cure.

TCRCure is a leading international company focused on streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry scale virus production, T cell genetic engineering, and immune cell manufacturing.
TRUST Platform
Our Unique Drug Discovery Platform. High-throughput discovery platform that identifies TCR in 6 weeks as compared to years of industry average.
CHECK-T Armored T-Cell Platform
CHECK-T Armored T-Cell Platform to Combat Immunosuppression. Next generation Cell drug armored with checkpoint blockade to improve solid tumor outcomes.
TURBO-T Platform
TURBO-T Platform for Tumor Cell Heterogeneity. New generation TCRT armored with tumor microenvironment reconditioning agent to enable the endogenous immunity against tumor heterogeneity.
GMP-grade and industry-scale vector production and cell manufacturing platform
Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.
NK Cell Platform
Optimize cord blood NK cell isolation, culturing, transgene, proliferation and differentiation technologies to ensure efficient transfection and amplification of NK cells. The unique drug design gives full play to the advantages of NK cells as general drugs and spot drugs.
Clinical immune monitoring
TCRCure’s deep sequencing and big data analysis platform supports immune monitoring services. This service can provide valuable data to pharmaceutical companies running clinical trials on immunotherapy drugs. TCRCure has already provided this service to many well-known pharmaceutical companies including BMS.
Scientific Publication
TCR-T technology is a T cell immunotherapy technique that engineers patient’s autologous T cells to express tumor antigen-specific T cell receptors (TCRs).
Core Team
Be the global leader of T cell cancer immunotherapy
So far, TCRCure has over 120 employees, with more than 40% of them being Ph.Ds. The company has several pipelines of TCR/CAR-T cell therapy products for solid tumors including cervical cancer, nasopharyngeal carcinoma,lung squamous carcinoma, ovarian cancer, endometrial cancer and brain cancer. TCRCure has started clinical trials and translational medicine research in coordination with the top hospitals in Chongqing, Chengdu, and Guangzhou, China.

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer